Global and regional prevalence, temporal trends, and projected trends of stroke after left ventricular assist device implantation: a systematic review and meta-analysis of 132,869 patients from 16 countries.

Expert Rev Med DevicesAug 2, 2026 (epub)
Clinical ResearchCardiologyOncology (Medical)

Chao Wan, Meng-Wei Ge, Wei Li et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the prevalence of stroke following left ventricular assist device (LVAD) implantation across 132,869 patients from 16 countries. The study found a global stroke prevalence of 14.0% (95% CI 12.0-15.0%), with the highest rates in Asia (18.0%) and the lowest in North America (12.0%). The prevalence has remained stable from 2008 to 2024 but is projected to decline in the next decade.

Key findings

  • Global stroke prevalence post-LVAD is 14.0% (95% CI 12.0-15.0%).
  • Stroke prevalence is highest in Asia at 18.0% and lowest in North America at 12.0%.
  • No significant change in stroke prevalence was observed from 2008 to 2024.
  • Exploratory projections suggest a declining trend in stroke prevalence over the next decade.

Why it matters

Understanding the prevalence and trends of stroke after LVAD implantation is crucial for clinicians to improve patient management and develop effective prevention strategies, ultimately enhancing patient outcomes.

Source

PubMed · PMID 42506988

Published in Expert Rev Med Devices. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.